Tellus BioVentures

Founded in 2019, Tellus BioVentures is a venture capital investment firm based in Miromar Lakes, Florida. It focuses on early-stage investments and company formation within the biotechnology sector.

Lonnie Moulder

General Partner

13 past transactions

Dianthus Therapeutics

Post in 2024
Dianthus Therapeutics is a clinical-stage biotechnology company focused on developing innovative treatments for severe autoimmune diseases through targeted therapies. The company's lead candidate, DNTH103, is a monoclonal antibody designed to selectively inhibit a specific component of the immune system, offering potential advantages over existing complement therapies. This treatment aims to improve safety and efficacy for patients suffering from serious autoimmune and inflammatory conditions. Dianthus is committed to advancing its pipeline of next-generation complement therapeutics, supported by a team of experienced professionals in the biotech and pharmaceutical sectors. The company envisions that DNTH103 could be administered as a self-injection for certain patients, enhancing convenience and accessibility in treatment.

Cantai Therapeutics

Seed Round in 2023
Cantai Therapeutics operates as a developer of drug candidates.

Vittoria Biotherapeutics

Venture Round in 2023
Vittoria Biotherapeutics is a biotechnology company focused on developing gene-edited T-cell therapies to address unmet medical needs in oncology and autoimmune diseases. It utilizes Senza5 technology to enhance the efficacy, safety, and practical utility of cell-based therapeutics, aiming to lower dosing requirements, ease preconditioning regimens, reduce manufacturing failures, and shorten vein-to-vein times. By expanding the potential applications of T-cell therapies, the company seeks to improve patient outcomes across its therapeutic pipeline and advance next-generation cell-based treatments from research toward clinical use.

Praeventix

Venture Round in 2022
Praeventix is an early-stage biotechnology company dedicated to developing innovative therapeutics for bowel diseases and other serotonergic-driven disorders. The company specializes in the discovery, research, and early clinical development of novel therapeutics that modulate signal transduction pathways. Praeventix aims to address unmet clinical needs in inflammatory bowel disease and has potential applications in treating dermatologic, autoimmune, and neurodegenerative diseases. Through its focused approach, the company seeks to provide physicians with effective treatment options for conditions such as chronic pruritus.

Zenas BioPharma

Series B in 2022
Zenas BioPharma is a clinical-stage biopharmaceutical company headquartered in Florida, USA, that specializes in developing immune-based therapies for patients. The company’s lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to target both CD19 and FcγRIIb, which are found in B cell lineages. This innovative approach aims to inhibit the activity of cells involved in various autoimmune diseases while preserving their presence, thus avoiding depletion. Through its focus on these advanced therapies, Zenas BioPharma seeks to address unmet medical needs in the treatment of autoimmune conditions.

Vittoria Biotherapeutics

Seed Round in 2022
Vittoria Biotherapeutics is a biotechnology company focused on developing gene-edited T-cell therapies to address unmet medical needs in oncology and autoimmune diseases. It utilizes Senza5 technology to enhance the efficacy, safety, and practical utility of cell-based therapeutics, aiming to lower dosing requirements, ease preconditioning regimens, reduce manufacturing failures, and shorten vein-to-vein times. By expanding the potential applications of T-cell therapies, the company seeks to improve patient outcomes across its therapeutic pipeline and advance next-generation cell-based treatments from research toward clinical use.

Dianthus Therapeutics

Series A in 2022
Dianthus Therapeutics is a clinical-stage biotechnology company focused on developing innovative treatments for severe autoimmune diseases through targeted therapies. The company's lead candidate, DNTH103, is a monoclonal antibody designed to selectively inhibit a specific component of the immune system, offering potential advantages over existing complement therapies. This treatment aims to improve safety and efficacy for patients suffering from serious autoimmune and inflammatory conditions. Dianthus is committed to advancing its pipeline of next-generation complement therapeutics, supported by a team of experienced professionals in the biotech and pharmaceutical sectors. The company envisions that DNTH103 could be administered as a self-injection for certain patients, enhancing convenience and accessibility in treatment.

Navrogen

Seed Round in 2021
Navrogen is a biopharmaceutical company based in Philadelphia, Pennsylvania, incorporated in 2017. The company specializes in developing technology platforms aimed at enhancing the immune system's ability to fight cancer. Navrogen focuses on identifying and addressing factors produced or induced by tumor cells that suppress the humoral immune response against cancer cells. By targeting these immunosuppressive effects, Navrogen aims to improve the efficacy of antibody-based drugs and develop more effective cancer treatments.

Interius BioTherapeutics

Series A in 2021
Interius BioTherapeutics is a biopharmaceutical company that develops in vivo cell-specific gene medicines to treat B cell lymphomas. Intravenous in vivo CAR treatment, which treats B cell lymphomas, is the company's flagship program. Its unique engineering provides exceptional target tissue specificity. The business is working on a second initiative to address autoimmune conditions. With the help of Interius, a novel and distinct therapeutic modality for the precise administration of gene therapies may soon be made available to patients in expanded care settings, without the need for preconditioning chemotherapy.

Zenas BioPharma

Series A in 2021
Zenas BioPharma is a clinical-stage biopharmaceutical company headquartered in Florida, USA, that specializes in developing immune-based therapies for patients. The company’s lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to target both CD19 and FcγRIIb, which are found in B cell lineages. This innovative approach aims to inhibit the activity of cells involved in various autoimmune diseases while preserving their presence, thus avoiding depletion. Through its focus on these advanced therapies, Zenas BioPharma seeks to address unmet medical needs in the treatment of autoimmune conditions.

TamuroBio

Seed Round in 2021
TamuroBio is a biotechnology company dedicated to developing innovative therapeutics for non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and Type 2 diabetes. The company focuses on creating pre-clinical candidates aimed at sequestering lipotoxic products to treat NASH, thereby helping patients prevent chronic liver disease and improve their quality of life. Through its targeted research and development efforts, TamuroBio aims to address significant unmet medical needs in the management of these conditions.

Aegle Therapeutics

Series A in 2020
Founded in 2013, Aegle Therapeutics is a biotechnology company developing extracellular vesicle (EV) therapies derived from mesenchymal stem cells. Its lead product aims to treat dystrophic epidermolysis bullosa, a rare pediatric skin disorder, by promoting healing and reducing scarring.

Interius BioTherapeutics

Private Equity Round in 2020
Interius BioTherapeutics is a biopharmaceutical company that develops in vivo cell-specific gene medicines to treat B cell lymphomas. Intravenous in vivo CAR treatment, which treats B cell lymphomas, is the company's flagship program. Its unique engineering provides exceptional target tissue specificity. The business is working on a second initiative to address autoimmune conditions. With the help of Interius, a novel and distinct therapeutic modality for the precise administration of gene therapies may soon be made available to patients in expanded care settings, without the need for preconditioning chemotherapy.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.